Since tanimilast had an effect greater than corticosteroids on Th1 cytokines from TCR-stimulated BAL cells, it can be suggested that there is therapeutic potential for this inhaled agent in severe asthma patients with increased airway levels of IFNγ which may be an indicator of significant Th1 inflammation and/or might reflect an ongoing anti-viral response (Kumar et al., 2006). This evidence concerns the gene IFNG and asthma.